← Leaderboards
David D Ho
Aaron Diamond Aids Research Center
$21,580,589
Attributed
$22,597,362
Total exposure
14
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2005–23$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$22,597,362 · 14
By mechanism
R01$11,026,788 · 5
DP1$4,401,050 · 1
U19$3,545,618 · 1
U01$2,055,129 · 1
R56$741,529 · 1
P30$391,328 · 2
Top collaborators
- Ciaran P Kelly5 shared
Most similar at Aaron Diamond Aids Research Center
Same institution · by research overlap
- Barbara L Shacklett$15,140,895
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoVirusCellsAntibodiesIn VitroAntiretroviral TherapyInfectionNeutralizing AntibodyViralPropertyMouse ModelHumanized MouseMediatingBindingEngineeringSurfaceHiv InfectionsBloodVirus DiseasesResponseMonoclonal AntibodiesHalf-LifeExperimental StudyMonkeys
Grant awards (43)
Quantifying Effector Functions of Anti-HIV IgG1 Antibodies In Vivo.$499,814
R01 · FY2023 · AI · contact PI
Multiplex Small Molecule Discovery to Identify Broad-Acting Viral Protease Inhibitors$3,545,618
U19 · FY2022 · AI · contact PI
Quantifying Effector Functions of Anti-HIV IgG1 Antibodies In Vivo.$1
R01 · FY2022 · AI · contact PI
Bispecific and Trispecific Anti-Env Antibodies for Eliminating HIV Reservoir Cells$713,872
R01 · FY2021 · AI · contact PI
Bispecific-Antibody-Drug Conjugates for Selective Targeting and Activation of the HIV Latent Reservoir$496,151
R01 · FY2021 · AI · contact PI
Quantifying Effector Functions of Anti-HIV IgG1 Antibodies In Vivo.$247,747
R01 · FY2021 · AI · contact PI
Quantifying Effector Functions of Anti-HIV IgG1 Antibodies In Vivo.$761,988
R01 · FY2020 · AI · contact PI
Bispecific and Trispecific Anti-Env Antibodies for Eliminating HIV Reservoir Cells$715,773
R01 · FY2020 · AI · contact PI
Bispecific-Antibody-Drug Conjugates for Selective Targeting and Activation of the HIV Latent Reservoir$488,051
R01 · FY2020 · AI · contact PI
Quantifying Effector Functions of Anti-HIV IgG1 Antibodies In Vivo.$614,457
R01 · FY2019 · AI · contact PI
Bispecific and Trispecific Anti-Env Antibodies for Eliminating HIV Reservoir Cells$443,662
R01 · FY2019 · AI · contact PI
Bispecific and Trispecific Anti-Env Antibodies for Eliminating HIV Reservoir Cells$368,083
R01 · FY2019 · AI · contact PI
Bispecific-Antibody-Drug Conjugates for Selective Targeting and Activation of the HIV Latent Reservoir$354,652
R01 · FY2019 · AI · contact PI
Quantifying Effector Functions of Anti-HIV IgG1 Antibodies In Vivo.$273,066
R01 · FY2019 · AI · contact PI
Bispecific-Antibody-Drug Conjugates for Selective Targeting and Activation of the HIV Latent Reservoir$205,834
R01 · FY2019 · AI · contact PI
Bispecific and Trispecific Anti-Env Antibodies for Eliminating HIV Reservoir Cells$910,463
R01 · FY2018 · AI · contact PI
Bispecific-Antibody-Drug Conjugates for Selective Targeting and Activation of the HIV Latent Reservoir$596,205
R01 · FY2018 · AI · contact PI
Bispecific and Trispecific Anti-Env Antibodies for Eliminating HIV Reservoir Cells$930,446
R01 · FY2017 · AI · contact PI
Bispecific-Antibody-Drug Conjugates for Selective Targeting and Activation of the HIV Latent Reservoir$595,153
R01 · FY2017 · AI · contact PI
Monthly Antiretroviral Therapy Using Multispecific HIV Neutralizing Antibodies$876,650
DP1 · FY2015 · DA · contact PI
Combination Clostridium Difficile Toxin and Adhesin Vaccine$353,006
R01 · FY2015 · AI · contact PI
Monthly Antiretroviral Therapy Using Multispecific HIV Neutralizing Antibodies$890,000
DP1 · FY2014 · DA · contact PI
Combination Clostridium Difficile Toxin and Adhesin Vaccine$362,505
R01 · FY2014 · AI · contact PI
Monthly Antiretroviral Therapy Using Multispecific HIV Neutralizing Antibodies$854,400
DP1 · FY2013 · DA · contact PI
Combination Clostridium Difficile Toxin and Adhesin Vaccine$349,463
R01 · FY2013 · AI · contact PI
Monthly Antiretroviral Therapy Using Multispecific HIV Neutralizing Antibodies$890,000
DP1 · FY2012 · DA · contact PI
Combination Clostridium Difficile Toxin and Adhesin Vaccine$227,044
R01 · FY2012 · AI · contact PI
Monthly Antiretroviral Therapy Using Multispecific HIV Neutralizing Antibodies$890,000
DP1 · FY2011 · DA · contact PI
Combination Clostridium Difficile Toxin and Adhesin Vaccine$741,529
R56 · FY2011 · AI · contact PI
PHASE I STUDY OF CLADE C DNA VACCINE IN HIV$260,771
M01 · FY2005 · RR
IN VITRO HIV/SIV ASSAYS USING RHESUS MACAQUE BLOOD$62,854
P51 · FY2005 · RR
IN VITRO HIV/SIV ASSAYS USING RHESUS MACAQUE BLOOD$47,161
P51 · FY2004 · RR
PHASE I STUDY OF CLADE C DNA VACCINE IN HIV$3,590
M01 · FY2004 · RR
IN VITRO HIV/SIV ASSAYS USING RHESUS MACAQUE BLOOD$61,544
P51 · FY2003 · RR
CENTER FOR AIDS RESEARCH$0
P30 · FY2002 · AI
CORE--VIROLOGY$0
P30 · FY2002 · AI
VIRAL AND IMMUNE CONSEQUENCES OF EARLY HIV1 THERAPY$1,020,826
U01 · FY2001 · AI
CORE--VIROLOGY$0
P30 · FY2001 · AI
CENTER FOR AIDS RESEARCH$0
P30 · FY2001 · AI
VIRAL AND IMMUNE CONSEQUENCES OF EARLY HIV1 THERAPY$1,034,303
U01 · FY2000 · AI
HIV1/SIV DYNAMICS AND LYMPHOCYTE TURNOVER$519,352
R01 · FY2000 · AI
CORE--VIROLOGY$195,664
P30 · FY2000 · AI
CENTER FOR AIDS RESEARCH$195,664
P30 · FY2000 · AI